RxDoctor Payments Data

Oliver Ryan, DPM

Foot & Ankle Surgery · Ypsilanti, MINPI 1750775896

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (39.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Arthrex at 49.8% of the total. Among foot & ankle surgery clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,166in general payments, 2019–2025

Across 290 payments — averaging $166.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$24K
  • Stryker$4K
  • Pinnacle, Inc$4K
  • Treace Medical Concepts, Inc.$3K
  • Kerecis Limited$3K
  • Integra Lifesciences Corporation$2K
  • plus $8K from 15 others

What the payments were for

  • Speaking & faculty fees$19,12540%
  • Travel & lodging$6,66514%
  • Food & beverage$16,98835%
  • Education$5,38711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,166 in reported general payments places this provider in the 95th percentile of 384 foot & ankle surgery providers in Michigan.

See all foot & ankle surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$122,255
Medicare patients
428
Services billed
1,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$3,820
Ketoconazole96$1,496
Econazole Nitrate31$975
Doxycycline Monohydrate20$192
Meloxicam77$148
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$114
Methylprednisolone18$100
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$80
Ciprofloxacin Hcl11$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$316$3,82012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 foot & ankle surgery providers in Michigan.

Other foot & ankle surgery in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →